Fabry Disease Symptoms: X-Linked Presentation in Males vs. Females

Fabry disease is an X-linked lysosomal storage disorder (GLA gene → α-galactosidase A deficiency → globotriaosylceramide [Gb3] accumulation). Males are typically severely affected; females have variable expression due to random X-inactivation.

Classic Male Phenotype (Type 1)

• Childhood/Adolescence:
  • Acroparesthesias: burning pain in hands/feet (triggered by heat, exercise, fever, stress)
  • Heat/exercise intolerance
  • Angiokeratomas: dark red punctate clusters (bathing trunk area, lips, mucosa)
  • Hypohidrosis/anhidrosis
  • Corneal verticillata (whorl-like opacity) — pathognomonic, asymptomatic
  • GI: abdominal pain, diarrhea, early satiety
• Adulthood (30s–50s):
  • Renal: proteinuria → ESRD (major cause of death pre-ERT)
  • Cardiac: LVH, fibrosis, arrhythmia, valvular thickening, HFpEF
  • CNS: TIA/stroke (vertebrobasilar), white matter lesions
  • Hearing loss, tinnitus

Female Phenotype (Variable)

• Random X-inactivation → mosaic Gb3 accumulation.
• Range: asymptomatic to equally severe as males.
• Typical: milder, later-onset acroparesthesias, corneal verticillata, mild renal/cardiac involvement.
• ~70% develop symptoms by age 40; ~20% reach ESRD.
• Cardiac variant (Type 2): later-onset LVH/fibrosis without classic early symptoms.

Diagnosis

• Males: Low α-Gal A activity (leukocytes, plasma, DBS) → confirmatory GLA sequencing.
• Females: Enzyme unreliable (normal in carriers); GLA sequencing required.
• Biomarkers: lyso-Gb3 (globotriaosylsphingosine) — elevated in both sexes; better for females.

Treatment

• Enzyme Replacement Therapy (ERT): Agalsidase alfa (0.2 mg/kg q2wk) or beta (1 mg/kg q2wk). Slows renal/cardiac decline; reduces pain.
• Chaperone Therapy: Migalastat (123 mg q2d) for amenable mutations (~35–50%). Oral; stabilizes mutant enzyme.
• Adjunctive: Neuropathic pain agents (gabapentin, pregabalin, duloxetine); ACEi/ARB for proteinuria; antiplatelet for stroke prevention.

Family Screening

X-linked: All daughters of affected male = carriers; 50% of sons of carrier female affected. Cascade testing essential.

Early diagnosis → early ERT → preserved organ function. Fabry is treatable—don't miss it.